Lifecare (LIFE) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
15 Oct, 2026Webcast presentation
CEO Joacim Holter scheduled to present a general status update and ongoing activities on 13 Jan 2026 at 11:30 CET.
Presentation in Norwegian, followed by a Q&A with questions submitted electronically during the webcast.
Presentation materials available on the website.
Technology focus
Medical sensor technology uses osmotic pressure to sense and monitor body analytes; focus on bringing next-generation continuous glucose monitoring systems to market.
Sensor technology is suitable for monitoring analytes and molecules in humans and pets.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lifecare
- NOK 45m raised as early clinical readings supported continued sensor development.LIFE
Q3 2022 - Six-month implant validation, regulatory clarity, and NOK 143m raised extend cash runway to 2027.LIFE
Q2 2026 - System-level validation, CE mark, and new funding drive cost reductions and commercialization.LIFE
Q1 2026 - System-level validation, CE marking, and NOK 80M funding secure near-term operations; more capital needed.LIFE
Q4 2025 - NOK 80 million funding secured; veterinary launch in 2026, human trials and launch in 2026–2027.LIFE
Q3 2025 - Longevity studies, automation, and strong cash position set stage for 2025 veterinary launch.LIFE
Q3 2024 - Sensor longevity breakthrough, new funding, and RemovAid acquisition drive growth.LIFE
Q2 2024 - Nearing scalable CGM launch, with strong R&D, funding milestones, and market growth prospects.LIFE
Q1 2025 - Euronext Oslo Børs listing, sensor advances, and major funding drive clinical trial readiness.LIFE
Q4 2024